The requirement for the IRE1-XBP1 pathway in myeloma and the recent discovery of a key function for this pathway in the progression of aggressive, triple-negative breast cancer has meant that IRE1 has become the focus of several drug discovery programs [12-16]. The gene discussed is XBP1; the disease is plasma cell myeloma.